These are top 10 stocks traded on the Robinhood UK platform in July
On Friday, H.C. Wainwright analyst Yi Chen adjusted the price target for Bausch & Lomb Corp. (NYSE:BLCO) to $15.00, down from the previous $20.00, while maintaining a Buy rating on the stock. The revision follows the company’s first-quarter financial report earlier in the week, which showed total revenue of $1,137 million. This marked a 3.5% year-over-year increase but fell short of the anticipated $1,150 million. The company maintains a solid gross profit margin of 61%, though InvestingPro analysis indicates it operates with a significant debt burden of nearly $5 billion.
The company experienced a net loss of $212 million, or $0.60 per share, which was significantly higher than the estimated loss of $59 million. The adjusted net loss stood at $54 million, or $0.15 per share, which was below the projected income of $53 million. Bausch & Lomb’s management highlighted that on a constant currency basis, revenue growth was 5%, but foreign exchange fluctuations negatively affected the results by $19 million.
The earnings report also included the financial impact of the enVista recall, which is estimated to have reduced revenue by approximately $55 million and adjusted EBITDA by about $65 million. The updated guidance provided by the company does not take into account the potential effects of tariffs. While currently trading near its InvestingPro Fair Value, the company maintains a "Fair" overall financial health score. Get detailed insights and 7 additional ProTips with a comprehensive Pro Research Report, available exclusively on InvestingPro.
Chen noted the lowered valuation multiples are a reflection of the uncertainties surrounding tariffs, leading to the reduced price target. Despite the cut in the price target, the analyst reiterated a Buy rating for Bausch & Lomb, indicating a continued positive outlook on the stock’s performance over the next 12 months.
In other recent news, Bausch + Lomb Corp reported its Q1 2025 earnings, revealing a miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.07 against a forecast of $0.02, and actual revenue of $1.14 billion compared to the expected $1.15 billion. Despite these setbacks, Bausch + Lomb raised its full-year revenue guidance to a range of $5.0 to $5.1 billion. The company experienced a 5% growth in revenue on a constant currency basis, driven by strong performance in its contact lens and eye health product segments. A voluntary recall of Envista lenses impacted revenue by $55 million, posing a risk to short-term financial performance. Analyst notes highlighted the company’s strategic initiatives, including the anticipated approval of the Elios MIGS glaucoma product by year-end. Bausch + Lomb’s core business continues to perform well, with expectations of constant currency revenue growth for the year. The company remains focused on innovation and expansion in its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.